newsfilter
← Latest News
Business Wire·

NantKwest, ImmunityBio Add Third-Line Cohort to Phase 2 Pancreatic Cancer Trial; Opens Study to Patients Who Have Failed All Approved Standards of Care

NK

EL SEGUNDO, Calif. & CULVER CITY, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, and ImmunityBio, a privately-held immunotherapy company, today announced they have added a third cohort to their ongoing Phase 2 trial of a novel immunotherapy for locally advanced or metastatic pancreatic cancer. The third cohort enables pancreatic cancer patients who have failed all approved standards of care to participate in the trial.